LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
E Crusoea, T Faconb, P Moreauc, I Spickad, K Suzukie, K Yongf, J Mikhaelg, T Fukaoh, N Armstrongi, T Martinj
a Hospital Universitario Professor Edgar Santos (HUPES), Salvador, Brazil; Rede D'or Oncologia, Salvador, Brazil
b Lille University Hospital, Lille, France
c University Hospital Hôtel-Dieu, Nantes, France
d 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic
e Japanese Red Cross Medical Center, Tokyo, Japan
f University College Hospital, London, United Kingdom
g Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, United States
h Sanofi, Global Oncology, Cambridge, United States
i Sanofi, Global Medical Affairs, Cambridge, United States
j University of California San Francisco Medical Center, San Francisco, United States
Ver másLido
1537
Vezesque se leu este artigo
670
Total PDF
867
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 12 | 105 | 82 | 187 |
| 2025 11 | 74 | 63 | 137 |
| 2025 10 | 33 | 17 | 50 |
| 2025 9 | 41 | 21 | 62 |
| 2025 8 | 32 | 17 | 49 |
| 2025 7 | 34 | 26 | 60 |
| 2025 6 | 28 | 16 | 44 |
| 2025 5 | 39 | 13 | 52 |
| 2025 4 | 28 | 10 | 38 |
| 2025 3 | 47 | 7 | 54 |
| 2025 2 | 37 | 17 | 54 |
| 2025 1 | 22 | 27 | 49 |
| 2024 12 | 21 | 15 | 36 |
| 2024 11 | 35 | 19 | 54 |
| 2024 10 | 28 | 20 | 48 |
| 2024 9 | 45 | 121 | 166 |
| 2024 8 | 34 | 18 | 52 |
| 2024 7 | 31 | 21 | 52 |
| 2024 6 | 28 | 21 | 49 |
| 2024 5 | 38 | 26 | 64 |
| 2024 4 | 33 | 12 | 45 |
| 2024 3 | 18 | 16 | 34 |
| 2024 2 | 9 | 11 | 20 |
| 2024 1 | 7 | 9 | 16 |
| 2023 12 | 6 | 15 | 21 |
| 2023 11 | 10 | 19 | 29 |
| 2023 10 | 4 | 11 | 15 |
Mostrar tudo
